Cargando…
A case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab
BACKGROUND: Hypereosinophilic dermatitis (HED) is a subtype of hypereosinophilic syndrome (HES). Glucocorticoids are preferred for treatment but carry substantial side effect profiles. Symptoms of HED may recur after systemic glucocorticoid tapering. As an interleukin-4 receptor (IL-4Rα) monoclonal...
Autores principales: | Jiang, Xiaoyun, Ye, Jun, Wu, Xia, Zhu, Jiang, Chen, Siji, Cheng, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010203/ https://www.ncbi.nlm.nih.gov/pubmed/36912915 http://dx.doi.org/10.1007/s00011-023-01715-1 |
Ejemplares similares
-
Hypereosinophilic Dermatitis: Successful Treatment with Dupilumab
por: Wu, Chenyu, et al.
Publicado: (2023) -
The complicated use of dupilumab in the treatment of atypical generalized pemphigus erythematosus: A report of two cases
por: Chen, Jie, et al.
Publicado: (2023) -
Dupilumab as a novel steroid-sparing treatment for hypereosinophilic syndrome
por: Du, Xiaoman, et al.
Publicado: (2022) -
Improvement in a patient with hypereosinophilic syndrome after initiation of dupilumab treatment
por: Wieser, Jill K., et al.
Publicado: (2020) -
New Onset of Alcohol Flushing in an Atopic Dermatitis Patient Treated with Dupilumab
por: Choi, Hoon, et al.
Publicado: (2023)